IL-13在支气管哮喘中的作用机制及治疗靶位  

The Mechanism and Targeted Treatment of IL-13 in Bronchial Asthma

作　　者：李晓霞[1] 杨春[1] 高光强[1] 梁红艳[1] 付冰冰[2] 姜晓峰[1] 

机构地区：[1]哈尔滨医科大学附属第四医院检验科,黑龙江哈尔滨150001 [2]佳木斯大学附属第一医院风湿免疫科,黑龙江佳木斯154002

出　　处：《现代生物医学进展》2017年第5期971-974,共4页Progress in Modern Biomedicine

基　　金：国家自然科学基金项目(81171657);高等学校博士学科点专项科研基金(博导类)项目(20112307110021)

摘　　要：支气管哮喘是由多种细胞包括气道炎性细胞、结构细胞和多种细胞组分参与的气道慢性炎症性疾病。其发病原因复杂,以反复发作的呼吸困难、气道的高反应性和慢性炎症为特点。细胞因子作为免疫活性细胞中的效应分子,具有的免疫调节作用,诸多学者认为白介素-13(interleukin-13,IL-13)在哮喘发病中扮演重要角色,其拮抗剂有望成为哮喘治疗的新方法,本文欲将IL-13的生物学功能、IL-13在支气管哮喘中的作用机制及干预治疗靶位加以综述,为制定哮喘防治策略、开发新治疗技术提供新思路。Bronchial asthma is a kind of chronic inflammatory disease of the airway which is involved of varieties of cells including airway inflammatory cells, structure of cells and various components involved in chronic inflammatory disease of the airway. Its pathogenesis is complex, features with recurrent breathing difficulties, chronic inflammation of the airway and bronchial hyperresponsiveness. As effector molecule in immune active cells, cytokines have effect of immune regulation. Many scholars believe that interleukin-13（IL-13） plays an important role in the occurrence of asthma. Its antagonist is be expected to be new therapeutic method of asthma.This article gives a summary of the physical functions of IL-13, and its relationship with the pathogenesis of bronchial asthma and an outlook of IL-13 as a new potential therapeutic targets in bronchial asthma. Provide new ideas for the development of asthma control strategy and the treatment strategy of asthma.

关 键 词：支气管哮喘 IL-13 治疗靶位 

分 类 号：R562.25[医药卫生—呼吸系统]